SCHEMBL7992736

SCHEMBL7992736

Cn1c(-c2ccccn2)nc(-c2ccc3c(c2)OCO3)c1Sc1ccc(Cl)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 2/20 0.62
TGFBR1 P36897 5/20 0.46
MAPT P10636 4/20 0.45
POLB P06746 3/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
RAB9A P51151 2/20 0.45
NPC1 O15118 1/20 0.45
TP53 P04637 1/20 0.45
PKM P14618 1/20 0.45
ESR2 Q92731 1/20 0.45
L3MBTL1 Q9Y468 3/20 0.45
GAA P10253 3/20 0.45
KMT2A Q03164 3/20 0.45
HTT P42858 2/20 0.45
TDP1 Q9NUW8 2/20 0.45
MAPK13 O15264 1/20 0.44
MAPK12 P53778 1/20 0.44
MAPK11 Q15759 1/20 0.44
MAPK14 Q16539 1/20 0.44
DCTPP1 Q9H773 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8005189 0.94 FAAH (0.62) FAAHTGFBR1MAPTPOLBSMN1; SMN2
SCHEMBL7993064 0.87 FAAH (0.76) FAAHMAPTPOLBSMN1; SMN2RAB9A
SCHEMBL8008516 0.83 FAAH (0.71) FAAHMAPTPOLBSMN1; SMN2NPC1
SCHEMBL1303197 0.82 FAAH (0.69) FAAHMAPTPOLBSMN1; SMN2RAB9A
SCHEMBL1303133 0.82 FAAH (0.69) FAAHMAPTPOLBSMN1; SMN2RAB9A
SCHEMBL1303678 0.82 FAAH (0.69) FAAHMAPTPOLBSMN1; SMN2RAB9A
SCHEMBL1304298 0.80 FAAH (0.67) FAAHTGFBR1POLBSMN1; SMN2L3MBTL1
SCHEMBL8005184 0.80 FAAH (0.61) FAAHMAPTPOLBSMN1; SMN2L3MBTL1
SCHEMBL12106804 0.80 FAAH (0.64) FAAHMAPTPOLBSMN1; SMN2RAB9A
SCHEMBL8005772 0.79 FAAH (0.61) FAAHMAPTPOLBSMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8455528-B2 Imidazole derivatives useful as inhibitors of FAAH MERCK SHARP & DOHME CORP. (US) 2013-06-04 US disclosed
US-8455528-B2 Imidazole derivatives useful as inhibitors of FAAH MERCK SHARP & DOHME CORP. (US) 2013-06-04 US disclosed
US-20110269769-A1 IMIDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH MERCK SHARP & DOHME CORP. 2011-11-03 US disclosed
US-20110269769-A1 IMIDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH MERCK SHARP & DOHME CORP. 2011-11-03 US disclosed
WO-2009152025-A1 IMIDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH MERCK & CO., INC. (US) 2009-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269769-A1 IMIDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH FAAH, FAAH2, HNMT FAAH 1/4885TGFBR1 4659/4885MAPT 657/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.